Proactive TDM Versus Standard Use of Biologics in Psoriasis

NCT06398106 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

210

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis Vulgaris

Interventions

DRUG: Proactive TDM-based dosing of secukinumab
DRUG: Proactive TDM-based dosing of ixekizumab
DRUG: Proactive TDM-based dosing of guselkumab

Sponsor

University Hospital, Ghent

Collaborators

[object Object]